Skip to content

Establish the optimum tDCS placement on cognition in people with Alzheimers disease

Establish the optimum tDCS placement on cognition in people with Alzheimers disease

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20250716008
Enrollment
51
Registered
2025-07-16
Start date
2025-07-23
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The primary health condition studied is Alzheimers disease. Alzheimer Disease Cognitive Dysfunction Gait Disorders, Neurologic Transcranial Direct Current Stimulation

Interventions

cathodal electrodes at FP1, FZ, C3, and F7 Mode of administration: Non-invasive brain stimulation using HD-tDCS device Setting: Administered in a clinical or research facility under supervision,Dose
HD-tDCS targeting the dorsolateral prefrontal cortex,HD-tDCS targeting the supplementary motor area,Sham HD-tDCS

Sponsors

MacKay Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 95 Years

Inclusion criteria

Inclusion criteria: 1. Age 60 years or older 2. Able to walk independently for more than 10 meters without assistive devices 3. Diagnosis of probable Alzheimers disease based on the National Institute on Aging and Alzheimers Association (NIA-AA) criteria 4. Clinical Dementia Rating (CDR) score of 1 or higher 5. Able to follow basic instructions

Exclusion criteria

Exclusion criteria: 1. Dementia caused by other neurological or psychiatric conditions 2. Severe depression based on standardized assessment 3. Presence of additional neurological disorders 4. Presence of psychiatric disorders 5. Medical conditions that interfere with participation in physical or cognitive assessments 6. Presence of metallic implants, pacemakers, or other contraindications to brain stimulation or EEG 7. Inability to follow instructions or complete the intervention due to physical or communication limitations unrelated to AD 8. Concurrent participation in other interventional studies

Design outcomes

Primary

MeasureTime frame
cognition two times, two days Montreal cognitive assessment,cognition two times, two days Mini-Mental State Examination,executive function two times, two days Trial making test,attention two times, two days Digital symbol modality test,episode memory two times, two days California verbal language test-short form,visuospatial perofrmance two times, two days Judgment of line orientation,naming two times, two days Boston naming test,depression two times, two days Geriatric depression scale

Secondary

MeasureTime frame
physical function two times, two days Timed Up and Go test,physical function two times, two days Short Physical Performance Battery,dual-task performance two times, two days cognitive dual task,dual-task performance two times, two days motor dual task,plasma biomarker two times, two days Brain-Derived Neurotrophic Factor,plasma biomarker two times, two days amyloid protein,plasma biomarker two times, two days tau protein,plasma biomarker two times, two days neurofilament light peptide

Countries

Taiwan

Contacts

Public ContactFangYu Cheng

MacKay Medical College

fycheng@mmu.edu.tw886226360303

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026